CN109589316A - 一种具有改善稳定性的微囊维生素c及其制备方法 - Google Patents
一种具有改善稳定性的微囊维生素c及其制备方法 Download PDFInfo
- Publication number
- CN109589316A CN109589316A CN201811475405.5A CN201811475405A CN109589316A CN 109589316 A CN109589316 A CN 109589316A CN 201811475405 A CN201811475405 A CN 201811475405A CN 109589316 A CN109589316 A CN 109589316A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- capsule
- micro
- vegetable oils
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 title claims abstract description 116
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 title claims abstract description 58
- 229930003268 Vitamin C Natural products 0.000 title claims abstract description 58
- 239000011718 vitamin C Substances 0.000 title claims abstract description 58
- 235000019154 vitamin C Nutrition 0.000 title claims abstract description 58
- 239000003094 microcapsule Substances 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 230000006872 improvement Effects 0.000 title description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 28
- 239000008158 vegetable oil Substances 0.000 claims abstract description 28
- 239000001856 Ethyl cellulose Substances 0.000 claims abstract description 27
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims abstract description 27
- 235000019325 ethyl cellulose Nutrition 0.000 claims abstract description 27
- 229920001249 ethyl cellulose Polymers 0.000 claims abstract description 27
- 125000005456 glyceride group Chemical group 0.000 claims abstract description 24
- 108010010803 Gelatin Proteins 0.000 claims abstract description 20
- 239000008273 gelatin Substances 0.000 claims abstract description 20
- 229920000159 gelatin Polymers 0.000 claims abstract description 20
- 235000019322 gelatine Nutrition 0.000 claims abstract description 20
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 20
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 19
- 239000001110 calcium chloride Substances 0.000 claims abstract description 19
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 19
- 235000011148 calcium chloride Nutrition 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 17
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 239000011265 semifinished product Substances 0.000 claims description 6
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004359 castor oil Substances 0.000 claims description 4
- 235000019438 castor oil Nutrition 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 4
- 229940074049 glyceryl dilaurate Drugs 0.000 claims description 4
- 238000002844 melting Methods 0.000 claims description 4
- 230000008018 melting Effects 0.000 claims description 4
- 235000012424 soybean oil Nutrition 0.000 claims description 4
- 239000003549 soybean oil Substances 0.000 claims description 4
- 235000019482 Palm oil Nutrition 0.000 claims description 3
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 3
- 239000008236 heating water Substances 0.000 claims description 3
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 3
- 239000002540 palm oil Substances 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 239000004519 grease Substances 0.000 claims description 2
- 239000003921 oil Substances 0.000 claims description 2
- 235000019198 oils Nutrition 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- -1 glycerol Ester Chemical class 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 10
- 239000000463 material Substances 0.000 abstract description 5
- 230000003026 anti-oxygenic effect Effects 0.000 abstract description 3
- 229910003460 diamond Inorganic materials 0.000 abstract description 3
- 239000010432 diamond Substances 0.000 abstract description 3
- 239000002904 solvent Substances 0.000 abstract description 3
- 238000009472 formulation Methods 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 150000003722 vitamin derivatives Chemical class 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 150000002083 enediols Chemical class 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229910021655 trace metal ion Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Food Science & Technology (AREA)
- Cardiology (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种具有改善稳定性的微囊维生素C及其制备方法，包括天然维生素C、甘油酯、硬化植物油、明胶、氯化钙、乙基纤维素，该微囊维生素C包含两层包埋薄膜。本发明通过对微囊壁材种类及含量的特定选择，采用独特的双层包埋工艺，得到包埋率大于95％的微囊维生素C，并且有效提高了维生素C的抗氧化性能，稳定性显著增加；本发明微囊维生素C制备过程中无需使用任何溶剂，实现零VOC排放，避免对环境造成污染，制备工艺简便易行，成本低廉。
Description
技术领域
本发明涉及医药保健食品技术领域，具体涉及一种具有改善稳定性的微囊维生素C及其制备方法。
背景技术
维生素C具有广泛的医疗和保健作用，能够促进胶原蛋白和组织间黏合质形成，抑制透明质酸酶和纤维蛋白质溶解酶，从而保持组织的完整性，适用于坏血症、脑溢血急性血氧症的防治，有助于帖的吸收，对血红蛋白和红细胞的成熟有一定的促进作用，可用于贫血、过敏性皮肤病、高血脂症和感冒的治疗，在医药、食品、日化等行业应用十分广泛。
但是，由于维生素C结构中的烯二醇基不稳定，维生素C容易受空气氧化而失去活性，特别是与微量金属离子接触，可使其氧化速度提高上万倍。目前，为缓解维生素C的氧化降解和流失，通常可通过将其微胶囊化以达到保护维生素C的目的。
维生素微囊较多采用熔化冷凝法，使用无毒且有一定营养价值的硬化油脂作壁材，在熔化条件下把维生素C分散并在冷却过程中形成包囊。现有技术中熔化冷凝法存在包埋材料单一，包裹效果及稳定性不佳，也难以适应多种气候条件下的长时间贮存；此外，该方法还存在温度较高维生素C容易失活等缺陷，因此有必要对维生素C微囊工艺进行相应研究及优化，改善微囊维生素C的稳定性，延长其贮存时间。
发明内容
本发明的目的在于提供一种具有改善稳定性的微囊维生素C，采用特殊双层包埋结构，有效提高了维生素C的抗氧化性能，稳定性显著增加。
本发明另一目的在于提供一种具有改善稳定性的微囊维生素C的制备方法，通过本发明制备方法得到的微囊维生素C包埋率达95％以上，制备过程中无需使用任何溶剂，实现零VOC排放，避免对环境造成污染，制备工艺简便易行，成本低廉。
为实现上述目的，本发明采用下述技术方案：
一种具有改善稳定性的微囊维生素C，包括天然维生素C、甘油酯、硬化植物油、明胶、氯化钙、乙基纤维素；
其中，所述微囊维生素C包含两层包埋薄膜；
其中，所述天然维生素C、甘油酯、硬化植物油、明胶、氯化钙、乙基纤维素的重量百分比为：天然维生素C40-55％、甘油酯8-12％、硬化植物油7-10％、明胶10-15％、氯化钙3-8％、乙基纤维素5-15％。
优选地，所述各组分重量百分比含量为：天然维生素C42-50％、甘油酯9-11％、硬化植物油8-9％、明胶12-14％、氯化钙5-7％、乙基纤维素7-12％。
优选地，所述甘油酯选自硬脂酸单甘油酯、月桂酸单甘油酯、1,3-二月桂酸甘油酯中一种或两种以上的混合物。
优选地，所述硬化植物油选自硬化棕榈油、硬化大豆油、硬化蓖麻油中的一种或两种以上的混合物。
优选地，所述硬化植物油熔点为30-60℃，优选40-55℃。
在微囊制备过程中，乙基纤维素的相对分子量对微囊聚合具有重大影响，释放速度很大程度上也受到相对分子量的影响，本发明中，乙基纤维素的相对分子量为3000-5000，优选3500-4500。
本发明还提供一种具有改善稳定性的微囊维生素C的制备方法，包括如下步骤：
SS1：按如下重量百分比称取原料：天然维生素C40-55％、甘油酯8-12％、硬化植物油7-10％、明胶10-15％、氯化钙3-8％、乙基纤维素5-15％；
SS2：将甘油酯和硬化植物油水浴加热至融化后混合均匀，控制混合物温度低于60℃；
SS3：将天然维生素C和乙基纤维素加入SS2所述混合物中，均匀分散后冷却，造粒得到半成品；
SS4：取明胶和氯化钠制成溶液，与SS3所述半成品均匀分散，用喷雾干燥机制成微囊，即得成品。
优选地，各组分重量百分比含量为：天然维生素C42-50％、甘油酯9-11％、硬化植物油8-9％、明胶12-14％、氯化钙5-7％、乙基纤维素7-12％。
优选地，所述甘油酯选自硬脂酸单甘油酯、月桂酸单甘油酯、1,3-二月桂酸甘油酯中一种或两种以上的混合物。
优选地，所述硬化植物油选自硬化棕榈油、硬化大豆油、硬化蓖麻油中的一种或两种以上的混合物。
优选地，所述硬化植物油熔点为30-60℃，优选40-55℃。
在微囊制备过程中，乙基纤维素的相对分子量对微囊聚合具有重大影响，释放速度很大程度上也受到相对分子量的影响，本发明中，乙基纤维素的相对分子量为3000-5000，优选3500-4500。
优选地，SS2中所述混合物温度为45-55℃。
优选地，SS4中所述溶液黏度为30000-40000mPa·s。
本发明的有益效果：通过对微囊壁材种类及含量的特定选择，及独特的双层包埋工艺，直接将微囊壁材熔化后与维生素C均匀分散，再经造粒、喷雾干燥工序，即得包埋率大于95％的微囊维生素C。该微囊维生素C由于采用了特殊双层包埋结构，有效提高了维生素C的抗氧化性能，稳定性显著增加。本发明微囊维生素C制备过程中无需使用任何溶剂，实现零VOC排放，避免对环境造成污染，制备工艺简便易行，成本低廉。
具体实施方式
下面将对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅是本发明的一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其它实施例，都属于本发明保护的范围。
实施例1
一种具有改善稳定性的微囊维生素C，包括天然维生素C、甘油酯、硬化植物油、明胶、氯化钙、乙基纤维素；其中，所述微囊维生素C包含两层包埋薄膜；其中，所述天然维生素C、甘油酯、硬化植物油、明胶、氯化钙、乙基纤维素的重量百分比为：天然维生素C 55％、甘油酯8％、硬化植物油10％、明胶10％、氯化钙4％、乙基纤维素13％。
该具有改善稳定性的微囊维生素C制备方法包括如下步骤：
SS1：按配方量重量百分比称取原料；
SS2：将甘油酯和硬化植物油水浴加热至融化后混合均匀，控制混合物温度为55℃；
SS3：将天然维生素C和乙基纤维素加入SS2所述混合物中，均匀分散后冷却，造粒得到半成品；
SS4：取明胶和氯化钠制成黏度为40000mPa·s的溶液，与SS3所述半成品均匀分散，用喷雾干燥机制成粒径小于80um的微囊，即得成品。
实施例2
微囊维生素C配方及制备方法与实施例1大致相同，差别在于各组分含量为：天然维生素C 50％、甘油酯9％、硬化植物油9％、明胶14％、氯化钙6％、乙基纤维素12％。
实施例3
微囊维生素C配方及制备方法与实施例1大致相同，差别在于各组分含量为：天然维生素C45％、甘油酯11％、硬化植物油10％、明胶14％、氯化钙8％、乙基纤维素12％。
对比例1
微囊维生素C配方及制备方法与实施例1大致相同，差别在于各组分含量为：天然维生素C 60％、甘油酯5％、硬化植物油5％、明胶8％、氯化钙2％、乙基纤维素20％。
对比例2
微囊维生素C配方及制备方法与实施例1大致相同，差别在于步骤SS2中温度为65℃。
对比例3
微囊维生素C配方及制备方法与实施例1大致相同，差别在于步骤SS4中溶液黏度为80000mPa·s。
微囊维生素C稳定性测试：将按实施例1-3及对比例1-3制得的微囊维生素C于35℃、相对湿度80％的环境下静置3个月，按照GB 5009.86-2016中的方法测定维生素C残余量并计算维生素C残余率。
测试结果如表1所示：
表1静置3个月后维生素C残余率
由表1结果可知，按照本发明配方含量及制备方法制得的微囊维生素C表现出较高的包埋率和优异的稳定性。
上述实施例为本发明较佳的实现方案，除此之外，本发明还可以其他方式实现，在不脱离本发明构思的前提下任何显而易见的替换均在本发明的保护范围之内。
Claims (14)
1.一种具有改善稳定性的微囊维生素C，包括天然维生素C、甘油酯、硬化植物油、明胶、氯化钙、乙基纤维素；
其中，所述微囊维生素C包含两层包埋薄膜；并且，
所述天然维生素C、甘油酯、硬化植物油、明胶、氯化钙、乙基纤维素的重量百分比为：天然维生素C 40-55％、甘油酯8-12％、硬化植物油7-10％、明胶10-15％、氯化钙3-8％、乙基纤维素5-15％。
2.根据权利要求1所述具有改善稳定性的为囊维生素C，各组分重量百分比含量为：天然维生素C 42-50％、甘油酯9-11％、硬化植物油8-9％、明胶12-14％、氯化钙5-7％、乙基纤维素7-12％。
3.根据权利要求1所述具有改善稳定性的为囊维生素C，所述甘油酯选自硬脂酸单甘油酯、月桂酸单甘油酯、1,3-二月桂酸甘油酯中一种或两种以上的混合物。
4.根据权利要求3所述具有改善稳定性的为囊维生素C，所述硬化植物油选自硬化棕榈油、硬化大豆油、硬化蓖麻油中的一种或两种以上的混合物。
5.根据权利要求2所述具有改善稳定性的为囊维生素C，所述硬化植物油熔点为30-60℃，优选40-55℃。
6.根据权利要求5所述具有改善稳定性的为囊维生素C，所述乙基纤维素的相对分子量为3000-5000，优选3500-4500。
7.一种具有改善稳定性的微囊维生素C的制备方法，包括如下步骤：
SS1：按如下重量百分比称取原料：天然维生素C 40-55％、甘油酯8-12％、硬化植物油7-10％、明胶10-15％、氯化钙3-8％、乙基纤维素5-15％；
SS2：将甘油酯和硬化植物油水浴加热至融化后混合均匀，控制混合物温度低于60℃；
SS3：将天然维生素C和乙基纤维素加入SS2所述混合物中，均匀分散后冷却，造粒得到半成品；
SS4：取明胶和氯化钠制成溶液，与SS3所述半成品均匀分散，用喷雾干燥机制成微囊，即得成品。
8.根据权利要求7所述制备方法，各组分重量百分比含量为：天然维生素C 42-50％、甘油酯9-11％、硬化植物油8-9％、明胶12-14％、氯化钙5-7％、乙基纤维素7-12％。
9.根据权利要求8所述制备方法，所述甘油酯选自硬脂酸单甘油酯、月桂酸单甘油酯、1,3-二月桂酸甘油酯中一种或两种以上的混合物。
10.根据权利要求9所述制备方法，所述硬化植物油选自硬化棕榈油、硬化大豆油、硬化蓖麻油中的一种或两种以上的混合物。
11.根据权利要求10所述制备方法，所述硬化植物油熔点为30-60℃，优选40-55℃。
12.根据权利要求11所述制备方法，所述乙基纤维素的相对分子量为3000-5000，优选3500-4500。
13.根据权利要求12所述制备方法，SS2中所述混合物温度为45-55℃。
14.根据权利要求13所述制备方法，SS4中所述溶液黏度为30000-40000mPa·s。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811475405.5A CN109589316B (zh) | 2018-12-04 | 2018-12-04 | 一种具有改善稳定性的微囊维生素c及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811475405.5A CN109589316B (zh) | 2018-12-04 | 2018-12-04 | 一种具有改善稳定性的微囊维生素c及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109589316A true CN109589316A (zh) | 2019-04-09 |
| CN109589316B CN109589316B (zh) | 2021-02-19 |
Family
ID=65961303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811475405.5A Active CN109589316B (zh) | 2018-12-04 | 2018-12-04 | 一种具有改善稳定性的微囊维生素c及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109589316B (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111528463A (zh) * | 2020-04-30 | 2020-08-14 | 北京万莱康营养与健康食品科学技术研究院有限公司 | 一种含优质坚果的生酮能量棒及其制备方法 |
| CN112806496A (zh) * | 2021-01-19 | 2021-05-18 | 吴华东 | 一种高稳定性禽用维生素制剂的制备方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01281140A (ja) * | 1988-04-30 | 1989-11-13 | Oogawara Kakoki Kk | マイクロカプセル化アスコルビン酸の製造方法 |
| KR20030077260A (ko) * | 2002-03-26 | 2003-10-01 | 주식회사 태평양 | Ｌ-아스코빌산 함유 다중공 고분자 마이크로캡슐, 이의제조방법 및 이를 함유하는 화장료 조성물 |
| CN1633999A (zh) * | 2004-11-19 | 2005-07-06 | 中国海洋大学 | 大蒜素微胶囊及其制备方法 |
| CN1650857A (zh) * | 2004-12-07 | 2005-08-10 | 武汉新华扬生物有限责任公司 | 维生素c的包被方法 |
| CN101411701A (zh) * | 2007-06-08 | 2009-04-22 | 佛山市海纳川药业有限公司 | 维生素c微囊制剂及其制备方法 |
-
2018
- 2018-12-04 CN CN201811475405.5A patent/CN109589316B/zh active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01281140A (ja) * | 1988-04-30 | 1989-11-13 | Oogawara Kakoki Kk | マイクロカプセル化アスコルビン酸の製造方法 |
| KR20030077260A (ko) * | 2002-03-26 | 2003-10-01 | 주식회사 태평양 | Ｌ-아스코빌산 함유 다중공 고분자 마이크로캡슐, 이의제조방법 및 이를 함유하는 화장료 조성물 |
| CN1633999A (zh) * | 2004-11-19 | 2005-07-06 | 中国海洋大学 | 大蒜素微胶囊及其制备方法 |
| CN1650857A (zh) * | 2004-12-07 | 2005-08-10 | 武汉新华扬生物有限责任公司 | 维生素c的包被方法 |
| CN101411701A (zh) * | 2007-06-08 | 2009-04-22 | 佛山市海纳川药业有限公司 | 维生素c微囊制剂及其制备方法 |
Non-Patent Citations (4)
| Title |
|---|
| COMUNIAN ET AL.: "Microencapsulation of ascorbic acid by complex coacervation: Protection and controlled release", 《FOOD RESEARCH INTERNATIONAL》 * |
| TRINDADE ET AL.: "The stability of ascorbic acid microencapsulated in granules of rice starch and in gum arabic", 《JOURNAL OF MICROENCAPSULATION》 * |
| 井乐刚等: "维生素C微胶囊的制备及应用的研究进展", 《化工进展》 * |
| 渠荣遴等: "双膜层包裹维生素C 的性能与在鲤鱼颗粒饲料中应用的试验研究", 《饲料工业》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111528463A (zh) * | 2020-04-30 | 2020-08-14 | 北京万莱康营养与健康食品科学技术研究院有限公司 | 一种含优质坚果的生酮能量棒及其制备方法 |
| CN112806496A (zh) * | 2021-01-19 | 2021-05-18 | 吴华东 | 一种高稳定性禽用维生素制剂的制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109589316B (zh) | 2021-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102716087B (zh) | 一种维生素粉末及其制备方法 | |
| EP1990045B1 (en) | Polysaccharide capsules and methods of preparation | |
| WO2020248295A1 (zh) | 一种植物软胶囊及其制备方法与用途 | |
| CN109589316A (zh) | 一种具有改善稳定性的微囊维生素c及其制备方法 | |
| CN105380924B (zh) | 一种壳寡糖胶囊剂及其制备方法 | |
| CN107550764A (zh) | 一种高稳定性的美藤果油水润q弹珠的制备方法 | |
| Leaw et al. | 3D printed corn starch–gelatin film with glycerol and hawthorn berry (Crataegus pinnatifida) extract | |
| CN105456064A (zh) | 一种抗衰老艾叶复合精油及其制备方法 | |
| DE112016006119T5 (de) | Ein Vitamin-, Carotinoid-Pulver sowie dessen Herstellungsverfahren und Anwendung | |
| CN105852131B (zh) | 制备符合有机食品加工标准的鱼油微胶囊的方法 | |
| CN104892825A (zh) | 一种负载薰衣草精油的甲基丙烯酸甲酯交联聚合物微粒及制备方法 | |
| CN105535261A (zh) | 一种艾叶保健精油及其制备方法 | |
| CN107823139A (zh) | 一种抗冻多重乳化凝胶组合物及用途 | |
| CN108043335A (zh) | 一种卷烟用易破碎胶囊的制备方法 | |
| CN105166908B (zh) | 一种富含ω‑3脂肪酸的微囊粉及其制备方法 | |
| CN107412014A (zh) | 一种含有美藤果油的纳米体系导入液及其制备方法 | |
| CN106727378A (zh) | 一种含有替格瑞洛主药的片剂组合物及其制备方法 | |
| CN103735460A (zh) | 天然植物精油果及其制备方法 | |
| CN108498480B (zh) | 中药软胶囊溶胶过程中防止明胶凝冻力降低的工艺方法 | |
| CN104719895A (zh) | 一种葡多酚微胶囊保健品及其制备方法 | |
| CN107496371B (zh) | 一种具有生物辅助性功能药理作用的淀粉基质空心胶囊 | |
| CN105801922B (zh) | 一种可应用于可食性包装领域的淀粉空囊及其制备方法 | |
| CN113491345A (zh) | 一种具有抗菌功能的爆珠壁材及爆珠的制备方法 | |
| CN111773198A (zh) | 新型艾地骨化醇软胶囊及其制备方法 | |
| CN111467318A (zh) | 一种罗望子胶植物肠溶空心胶囊及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20210125 Address after: 450002 Henan Agricultural University, 95 Wenhua Road, Henan, Zhengzhou Applicant after: HENAN AGRICULTURAL University Applicant after: HENAN KANGBOER AGRICULTURAL TECHNOLOGY Co.,Ltd. Applicant after: HENAN BRIGHT ANIMAL PHARMACEUTICAL Co.,Ltd. Applicant after: Henan Institute of Modern Chinese Veterinary Medicine Applicant after: HENAN LYUXIANG AGRICULTURAL TECHNOLOGY Co.,Ltd. Address before: 450002 Henan Agricultural University, 95 Wenhua Road, Henan, Zhengzhou Applicant before: HENAN AGRICULTURAL University Applicant before: HENAN KANGBOER AGRICULTURAL TECHNOLOGY Co.,Ltd. Applicant before: HENAN BRIGHT ANIMAL PHARMACEUTICAL Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231222 Address after: 450000 No. 15, Longzihu University Park, Zhengdong New Area, Zhengzhou City, Henan Province Patentee after: HENAN AGRICULTURAL University Patentee after: HENAN KANGBOER AGRICULTURAL TECHNOLOGY Co.,Ltd. Patentee after: Henan Highlight Pharmaceutical Co.,Ltd. Patentee after: Henan Institute of Modern Chinese Veterinary Medicine Patentee after: HENAN LYUXIANG AGRICULTURAL TECHNOLOGY Co.,Ltd. Address before: 450002 Henan Agricultural University, 95 Wenhua Road, Henan, Zhengzhou Patentee before: HENAN AGRICULTURAL University Patentee before: HENAN KANGBOER AGRICULTURAL TECHNOLOGY Co.,Ltd. Patentee before: HENAN BRIGHT ANIMAL PHARMACEUTICAL CO.,LTD. Patentee before: Henan Institute of Modern Chinese Veterinary Medicine Patentee before: HENAN LYUXIANG AGRICULTURAL TECHNOLOGY Co.,Ltd. |
|
| TR01 | Transfer of patent right |